OTLK — Outlook Therapeutics Share News
0.000.00%
Last trade - 00:00- $126.42m
- $133.41m
- $1.41m
U.S. STOCKS ON THE MOVE-Amkor Technology, Dynatrace, Corvex
Outlook Therapeutics rises after US FDA accepts eye disease treatment for review
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Outlook Therapeutics rises after US FDA accepts to review eye disease treatment
Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment
Brief: Outlook Therapeutics Says FDA Finds Substantial Evidence Of Effectiveness For Lytenava In nAMD
Outlook Therapeutics Q2 adjusted EPS misses analyst expectations
Brief: Outlook Therapeutics Inc - Enters ATM Offering Agreement With H.C. Wainwright For Up To $100 Million - SEC Filing
Brief: Outlook Therapeutics - Enters Sales Agreement With H.C. Wainwright To Offer And Sell Common Stock Up To $100 Million - SEC Filing
Brief: Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
Outlook Therapeutics rises as FDA agrees to review eye drug decision
Brief: Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA
Brief: Outlook Therapeutics Announces Proposed Public Offering
Brief: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing And Amendment To Existing Convertible Note
Chinese banks boost loans to tech sector as Beijing ramps up AI push
Brief: Outlook Therapeutics Provides Update Following Type A Meeting With FDA
Outlook Therapeutics swings to Q1 net loss